Interleukin-27 binds Interleukin-27 receptor

Stable Identifier
Reaction [binding]
Homo sapiens
IL27(complex of IL27:EBI3) binds IL27R(complex of IL27RA:IL6ST), IL27:EBI3 binds IL27RA:IL6ST
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Interleukin-27 is a heterodimer composed of Interleukin-27 subunit alpha (IL27) and Epstein-Barr virus-induced gene 3 (EBI3). It binds to the Interleukin-27 heterodimeric receptor, which is composed of Interleukin-27 receptor subunit alpha (IL27RA, WSX-1) and Interleukin-6 receptor subunit beta (IL6ST, gp130). IL6ST is a signal transducing protein that is a component of several other cytokine receptors including the Interleukin-6 and Interleukin-11 receptors (Pflanz et al. 2004). In the absence of IL27RA, Interleukin-27 can bind to IL6ST but with low affinity (Jia et al. 2016).
Regulation: IL27RA can be cleaved releasing a soluble form (sIL27RA) that can bind to Interleukin-27 and antagonize Interleukin-27 binding to its heterodimer receptor (Dietrich et al. 2014).

Literature References
PubMed ID Title Journal Year
14764690 WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27

Pflanz, S, Hibbert, L, Mattson, J, Rosales, R, Vaisberg, E, Bazan, JF, Phillips, JH, McClanahan, TK, de Waal Malefyt, R, Kastelein, RA

J Immunol 2004
27119567 IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs

Jia, H, Dilger, P, Bird, C, Wadhwa, M

J. Interferon Cytokine Res. 2016
24771852 A soluble form of IL-27Rα is a natural IL-27 antagonist

Dietrich, C, Candon, S, Ruemmele, FM, Devergne, O

J. Immunol. 2014
This event is regulated
Negatively by

A naturally occurring soluble form of Interleukin-27 receptor subunit alpha(IL-27Ralpha) is termed soluble Interleukin-27 receptor subunit alpha (sIL-27Ralpha)and it is produced by human activated CD4(+) and CD8(+) T cells, B cells, myeloid cells, and various cell lines. sIL-27Rα is present at a mean concentration of 10,344(+/- 1,274) pg/ml in the sera from healthy individuals.Importantly, natural sIL-27Ralpha binds rIL-27(the heterodimer composer by the Interleukin-27 subunit alpha and Interleukin-27 subunit beta), inhibits IL-27 binding to its cell surface receptor, and is a potent inhibitor of IL-27 signaling, as shown by its ability to specifically block IL-27-mediated STAT activation, at low molar excess over IL-27. Also, we found that serum levels of sIL-27Ralpha were elevated in patients with Crohn's disease, a Th1-mediated disease

Cite Us!